$EPZM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Epizyme, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Epizyme, Inc.. Get notifications about new insider transactions in Epizyme, Inc. for free.
Page: < prev 1 2 3 4 5 6 ... 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | J | 0.00 | 38,646 | 0 | 39,297 | 651 to 39.3 K (+5,936.41 %) |
| Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | J | 0.00 | 767,500 | 0 | 0 | 767.5 K to 0 (-100.00 %) |
| Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | J | 0.00 | 767,500 | 0 | 767,500 | 0 to 767.5 K |
| Jun 26 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Sell | J | 0.00 | 2,500,000 | 0 | 3,971,018 | 6.5 M to 4 M (-38.63 %) |
| Jun 17 2019 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 11.97 | 1,195 | 14,304 | 35,699 | 36.9 K to 35.7 K (-3.24 %) |
| Jun 14 2019 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 12.10 | 203 | 2,456 | 497 | 700 to 497 (-29.00 %) |
| Jun 14 2019 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Grant | A | 0.00 | 700 | 0 | 700 | 0 to 700 |
| Jun 14 2019 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 4,000 | 0 | 36,894 | 32.9 K to 36.9 K (+12.16 %) |
| Jun 14 2019 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 12.10 | 1,185 | 14,339 | 39,032 | 40.2 K to 39 K (-2.95 %) |
| Jun 14 2019 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 4,000 | 0 | 40,217 | 36.2 K to 40.2 K (+11.04 %) |
| Jun 14 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 12.10 | 2,074 | 25,095 | 84,994 | 87.1 K to 85 K (-2.38 %) |
| Jun 14 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 7,000 | 0 | 87,068 | 80.1 K to 87.1 K (+8.74 %) |
| Jun 07 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
| Jun 07 2019 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 12.39 | 1,891 | 23,429 | 13,979 | 12.1 K to 14 K (+15.64 %) |
| Jun 07 2019 | EPZM | Epizyme, Inc. | SEIDENBERG BETH C | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
| Jun 07 2019 | EPZM | Epizyme, Inc. | SEIDENBERG BETH C | Director | Grant | A | 12.39 | 1,024 | 12,687 | 7,471 | 6.4 K to 7.5 K (+15.88 %) |
| Jun 07 2019 | EPZM | Epizyme, Inc. | GOLDFISCHER CARL | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
| Jun 07 2019 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
| Jun 07 2019 | EPZM | Epizyme, Inc. | Allen Andrew R | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
| Jun 07 2019 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
| Jun 07 2019 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Grant | A | 12.39 | 897 | 11,114 | 3,775 | 2.9 K to 3.8 K (+31.17 %) |
| Jun 07 2019 | EPZM | Epizyme, Inc. | Giordano Michael F | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
| Jun 07 2019 | EPZM | Epizyme, Inc. | POPS RICHARD F | Director | Option Exercise | A | 13.74 | 17,633 | 242,277 | 17,633 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | A | 9.12 | 151,620 | 1,382,774 | 151,620 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Grant | A | 0.00 | 32,894 | 0 | 36,217 | 3.3 K to 36.2 K (+989.89 %) |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Option Exercise | A | 9.12 | 24,523 | 223,650 | 24,523 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Option Exercise | A | 9.12 | 151,620 | 1,382,774 | 151,620 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 32,894 | 0 | 32,894 | 0 to 32.9 K |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 9.12 | 347,464 | 3,168,872 | 347,464 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 75,383 | 0 | 80,068 | 4.7 K to 80.1 K (+1,609.03 %) |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | A | 9.12 | 151,620 | 1,382,774 | 151,620 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Grant | A | 0.00 | 32,894 | 0 | 36,217 | 3.3 K to 36.2 K (+989.89 %) |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Option Exercise | A | 9.12 | 24,523 | 223,650 | 24,523 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Option Exercise | A | 9.12 | 151,620 | 1,382,774 | 151,620 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 32,894 | 0 | 32,894 | 0 to 32.9 K |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 9.12 | 347,464 | 3,168,872 | 347,464 | |
| Jan 28 2019 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 75,383 | 0 | 80,068 | 4.7 K to 80.1 K (+1,609.03 %) |
| Oct 05 2018 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | P | 9.00 | 416,667 | 3,750,003 | 6,471,018 | 6.1 M to 6.5 M (+6.88 %) |
| Jul 24 2018 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Option Exercise | A | 13.35 | 170,000 | 2,269,500 | 170,000 | |
| Jul 02 2018 | EPZM | Epizyme, Inc. | SEIDENBERG BETH C | Director | Grant | A | 13.55 | 3,247 | 43,997 | 6,447 | 3.2 K to 6.4 K (+101.47 %) |
| Jul 02 2018 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Grant | A | 13.55 | 6,088 | 82,492 | 12,088 | 6 K to 12.1 K (+101.47 %) |
| Jul 02 2018 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Grant | A | 13.55 | 2,878 | 38,997 | 2,878 | 0 to 2.9 K |
| May 31 2018 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Option Exercise | A | 17.00 | 12,500 | 212,500 | 12,500 | |
| May 31 2018 | EPZM | Epizyme, Inc. | Allen Andrew R | Director | Option Exercise | A | 17.00 | 12,500 | 212,500 | 12,500 | |
| May 31 2018 | EPZM | Epizyme, Inc. | POPS RICHARD F | Director | Option Exercise | A | 17.00 | 12,500 | 212,500 | 12,500 | |
| May 31 2018 | EPZM | Epizyme, Inc. | SEIDENBERG BETH C | Director | Option Exercise | A | 17.00 | 12,500 | 212,500 | 12,500 | |
| May 31 2018 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 17.00 | 12,500 | 212,500 | 12,500 | |
| May 31 2018 | EPZM | Epizyme, Inc. | GOLDFISCHER CARL | Director | Option Exercise | A | 17.00 | 12,500 | 212,500 | 12,500 | |
| May 31 2018 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Option Exercise | A | 17.00 | 12,500 | 212,500 | 12,500 | |
| Mar 12 2018 | EPZM | Epizyme, Inc. | Giordano Michael F | Director | Option Exercise | A | 17.60 | 25,000 | 440,000 | 25,000 | |
| Feb 13 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | A | 16.00 | 106,344 | 1,701,504 | 106,344 | |
| Feb 13 2018 | EPZM | Epizyme, Inc. | Graf Susan E | Chief Business Offi ... | Option Exercise | A | 16.00 | 106,344 | 1,701,504 | 106,344 | |
| Feb 13 2018 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 16.00 | 265,860 | 4,253,760 | 265,860 | |
| Feb 13 2018 | EPZM | Epizyme, Inc. | Fleming Suzanne | SVP | Option Exercise | A | 16.00 | 29,002 | 464,032 | 29,002 | |
| Feb 06 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | M | 9.58 | 72,264 | 692,289 | 0 | |
| Feb 06 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Sell | S | 17.20 | 519 | 8,927 | 2,603 | 3.1 K to 2.6 K (-16.62 %) |
| Feb 06 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Sell | S | 16.63 | 71,745 | 1,192,768 | 3,122 | 74.9 K to 3.1 K (-95.83 %) |
| Feb 06 2018 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Buy | M | 9.58 | 72,264 | 692,289 | 74,867 | 2.6 K to 74.9 K (+2,776.18 %) |
| Oct 25 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Option Exercise | M | 8.98 | 15,000 | 134,700 | 5,500 | |
| Oct 25 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Sell | S | 16.44 | 15,000 | 246,591 | 8,123 | 23.1 K to 8.1 K (-64.87 %) |
| Oct 25 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Buy | M | 8.98 | 15,000 | 134,700 | 23,123 | 8.1 K to 23.1 K (+184.66 %) |
| Sep 26 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Option Exercise | M | 8.98 | 15,000 | 134,700 | 15,725 | |
| Sep 26 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Sell | S | 16.81 | 15,000 | 252,077 | 8,123 | 23.1 K to 8.1 K (-64.87 %) |
| Sep 26 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Buy | M | 8.98 | 15,000 | 134,700 | 23,123 | 8.1 K to 23.1 K (+184.66 %) |
| Sep 21 2017 | EPZM | Epizyme, Inc. | Fleming Suzanne | SVP | Option Exercise | A | 18.70 | 90,180 | 1,686,366 | 90,180 | |
| Sep 18 2017 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Buy | P | 15.25 | 200,000 | 3,050,000 | 6,054,351 | 5.9 M to 6.1 M (+3.42 %) |
| Aug 28 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Option Exercise | M | 8.98 | 15,000 | 134,700 | 25,950 | |
| Aug 28 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Sell | S | 15.68 | 15,000 | 235,266 | 7,228 | 22.2 K to 7.2 K (-67.48 %) |
| Aug 28 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Buy | M | 8.98 | 15,000 | 134,700 | 22,228 | 7.2 K to 22.2 K (+207.53 %) |
| Aug 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 778 | 0 | 13,992 | |
| Aug 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,682 | 0 | 30,274 | |
| Aug 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 778 | 0 | 45,446 | 44.7 K to 45.4 K (+1.74 %) |
| Aug 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 1,682 | 0 | 44,668 | 43 K to 44.7 K (+3.91 %) |
| Jul 26 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Option Exercise | M | 8.98 | 15,000 | 134,700 | 36,175 | |
| Jul 26 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Sell | S | 13.44 | 15,000 | 201,572 | 7,228 | 22.2 K to 7.2 K (-67.48 %) |
| Jul 26 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Buy | M | 8.98 | 15,000 | 134,700 | 22,228 | 7.2 K to 22.2 K (+207.53 %) |
| Jul 12 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 777 | 0 | 14,770 | |
| Jul 12 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,682 | 0 | 31,956 | |
| Jul 12 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 777 | 0 | 42,986 | 42.2 K to 43 K (+1.84 %) |
| Jul 12 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 1,682 | 0 | 42,209 | 40.5 K to 42.2 K (+4.15 %) |
| Jul 05 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Sell | S | 15.50 | 3,024 | 46,872 | 40,529 | 43.6 K to 40.5 K (-6.94 %) |
| Jun 27 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Option Exercise | M | 8.98 | 15,000 | 134,700 | 46,400 | |
| Jun 27 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Sell | S | 14.87 | 15,000 | 223,115 | 7,228 | 22.2 K to 7.2 K (-67.48 %) |
| Jun 27 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Buy | M | 8.98 | 15,000 | 134,700 | 22,228 | 7.2 K to 22.2 K (+207.53 %) |
| Jun 26 2017 | EPZM | Epizyme, Inc. | BATE KENNETH | Director | Option Exercise | A | 13.65 | 12,500 | 170,625 | 12,500 | |
| Jun 26 2017 | EPZM | Epizyme, Inc. | MOTT DAVID M | Director | Option Exercise | A | 13.65 | 12,500 | 170,625 | 12,500 | |
| Jun 26 2017 | EPZM | Epizyme, Inc. | Allen Andrew R | Director | Option Exercise | A | 13.65 | 12,500 | 170,625 | 12,500 | |
| Jun 26 2017 | EPZM | Epizyme, Inc. | POPS RICHARD F | Director | Option Exercise | A | 13.65 | 12,500 | 170,625 | 12,500 | |
| Jun 26 2017 | EPZM | Epizyme, Inc. | GOLDFISCHER CARL | Director | Option Exercise | A | 13.65 | 12,500 | 170,625 | 12,500 | |
| Jun 26 2017 | EPZM | Epizyme, Inc. | SEIDENBERG BETH C | Director | Option Exercise | A | 13.65 | 12,500 | 170,625 | 12,500 | |
| Jun 12 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 777 | 0 | 15,547 | |
| Jun 12 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,682 | 0 | 33,638 | |
| Jun 12 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 777 | 0 | 43,553 | 42.8 K to 43.6 K (+1.82 %) |
| Jun 12 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 1,682 | 0 | 42,776 | 41.1 K to 42.8 K (+4.09 %) |
| Jun 07 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Option Exercise | M | 3.54 | 2,500 | 8,850 | 36,050 | |
| Jun 07 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Sell | S | 13.45 | 2,500 | 33,625 | 31,538 | 34 K to 31.5 K (-7.34 %) |
| Jun 07 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Buy | M | 3.54 | 2,500 | 8,850 | 34,038 | 31.5 K to 34 K (+7.93 %) |
| May 26 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Option Exercise | M | 8.98 | 15,000 | 134,700 | 56,625 | |
| May 26 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Sell | S | 16.11 | 15,000 | 241,664 | 7,228 | 22.2 K to 7.2 K (-67.48 %) |
| May 26 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Buy | M | 8.98 | 15,000 | 134,700 | 22,228 | 7.2 K to 22.2 K (+207.53 %) |
| May 11 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 778 | 0 | 16,324 | |
| May 11 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,682 | 0 | 35,320 | |
| May 11 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 778 | 0 | 41,094 | 40.3 K to 41.1 K (+1.93 %) |
| May 11 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 1,682 | 0 | 40,316 | 38.6 K to 40.3 K (+4.35 %) |
| May 03 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Option Exercise | M | 3.54 | 5,000 | 17,700 | 38,550 | |
| May 03 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Sell | S | 17.44 | 5,000 | 87,213 | 31,538 | 36.5 K to 31.5 K (-13.68 %) |
| May 03 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Buy | M | 3.54 | 5,000 | 17,700 | 36,538 | 31.5 K to 36.5 K (+15.85 %) |
| Apr 11 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 777 | 0 | 17,102 | |
| Apr 11 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,682 | 0 | 37,002 | |
| Apr 11 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 777 | 0 | 38,634 | 37.9 K to 38.6 K (+2.05 %) |
| Apr 11 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 1,682 | 0 | 37,857 | 36.2 K to 37.9 K (+4.65 %) |
| Apr 05 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Option Exercise | M | 3.54 | 3,000 | 10,620 | 43,550 | |
| Apr 05 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Option Exercise | M | 2.19 | 2,000 | 4,380 | 0 | |
| Apr 05 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Sell | S | 16.36 | 2,500 | 40,896 | 31,538 | 34 K to 31.5 K (-7.34 %) |
| Apr 05 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Sell | S | 16.36 | 2,500 | 40,909 | 34,038 | 36.5 K to 34 K (-6.84 %) |
| Apr 05 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Buy | M | 3.54 | 3,000 | 10,620 | 36,538 | 33.5 K to 36.5 K (+8.95 %) |
| Apr 05 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Buy | M | 2.19 | 2,000 | 4,380 | 33,538 | 31.5 K to 33.5 K (+6.34 %) |
| Apr 03 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Sell | S | 17.09 | 2,013 | 34,394 | 36,175 | 38.2 K to 36.2 K (-5.27 %) |
| Mar 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 777 | 0 | 17,879 | |
| Mar 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,682 | 0 | 38,684 | |
| Mar 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 777 | 0 | 38,188 | 37.4 K to 38.2 K (+2.08 %) |
| Mar 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 1,682 | 0 | 37,411 | 35.7 K to 37.4 K (+4.71 %) |
| Mar 02 2017 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Grant | A | 6.21 | 1,708 | 10,613 | 1,708 | 0 to 1.7 K |
| Mar 02 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Grant | A | 6.21 | 1,708 | 10,613 | 7,228 | 5.5 K to 7.2 K (+30.94 %) |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 778 | 0 | 18,656 | |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,681 | 0 | 40,366 | |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | A | 12.45 | 61,037 | 759,911 | 61,037 | |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 778 | 0 | 35,729 | 35 K to 35.7 K (+2.23 %) |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 1,681 | 0 | 34,951 | 33.3 K to 35 K (+5.05 %) |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 12.45 | 335,704 | 4,179,515 | 335,704 | |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Copeland Robert A | President of Resear ... | Option Exercise | A | 12.45 | 97,659 | 1,215,855 | 97,659 | |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Option Exercise | A | 12.45 | 122,074 | 1,519,821 | 122,074 | |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Graf Susan E | Chief Business Offi ... | Option Exercise | A | 12.45 | 109,866 | 1,367,832 | 109,866 | |
| Feb 09 2017 | EPZM | Epizyme, Inc. | Ros Matthew | Chief Operating Off ... | Option Exercise | A | 12.45 | 109,866 | 1,367,832 | 109,866 | |
| Feb 07 2017 | EPZM | Epizyme, Inc. | Conroy Kevin T | Director | Option Exercise | A | 12.05 | 25,000 | 301,250 | 25,000 | |
| Jan 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 777 | 0 | 19,434 | |
| Jan 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,682 | 0 | 42,047 | |
| Jan 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Sell | S | 12.04 | 1,013 | 12,194 | 33,270 | 34.3 K to 33.3 K (-2.95 %) |
| Jan 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 777 | 0 | 34,283 | 33.5 K to 34.3 K (+2.32 %) |
| Jan 10 2017 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 1,682 | 0 | 33,506 | 31.8 K to 33.5 K (+5.29 %) |
| Dec 12 2016 | EPZM | Epizyme, Inc. | Ho Peter Tai-Ching | Chief Development O ... | Sell | S | 10.89 | 200 | 2,179 | 5,520 | 5.7 K to 5.5 K (-3.50 %) |
| Dec 12 2016 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 777 | 0 | 20,211 | |
| Dec 12 2016 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,682 | 0 | 43,729 | |
| Dec 12 2016 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Sell | S | 11.03 | 1,013 | 11,172 | 31,824 | 32.8 K to 31.8 K (-3.08 %) |
| Dec 12 2016 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 777 | 0 | 32,837 | 32.1 K to 32.8 K (+2.42 %) |
| Dec 12 2016 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 1,682 | 0 | 32,060 | 30.4 K to 32.1 K (+5.54 %) |
| Nov 10 2016 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 778 | 0 | 20,988 | |
| Nov 10 2016 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Option Exercise | M | 0.00 | 1,682 | 0 | 45,411 | |
| Nov 10 2016 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Sell | S | 10.40 | 1,013 | 10,535 | 30,378 | 31.4 K to 30.4 K (-3.23 %) |
| Nov 10 2016 | EPZM | Epizyme, Inc. | Singer Andrew E. | EVP & CFO | Buy | M | 0.00 | 778 | 0 | 31,391 | 30.6 K to 31.4 K (+2.54 %) |